Introduction
Pathological myopia is a major cause of legal blindness in developed countries [1] . Choroidal neovascularization (CNV) is an important cause of visual loss among highly myopic patients with a prevalence of 5-11% [2, 3] . Pathological myopia is the most common cause of CNV in young individuals [4] . Natural history of myopic CNV is considered to be poor, with a high proportion of patients having a significant loss of visual acuity [5] [6] [7] [8] . Nowadays, photodynamic therapy (PDT) with verteporfin is the only approved treatment by regulatory authorities for myopic CNV. However, in the VIPm study, treated eyes did not achieve the main outcome by the end of the second year of follow-up [9] . Anti-VEGF drugs have been used off-label to treat myopic CNV. We have published the 6-month and 12-month results of myopic CNV treated with intravitreal ranibizumab with good outcomes [10, 11] . In the present study, we report the 36-month follow-up of myopic CNV treated by intravitreal ranibizumab.
Patients and Methods
A retrospective, institutional study was performed in 40 eyes of 39 patients with active subfoveal or juxtafoveal myopic CNV treated with an intravitreal injection (nonloading dose) of 0.5 mg of ranibizumab and followed for 3 years.
Fifteen eyes had previously undergone PDT for myopic CNV at least 3 months before the first ranibizumab treatment. No additional PDT was performed during the follow-up.
The inclusion criteria were: (1) highly myopic eyes with a spherical equivalent 6 -6 dpt or an axial length 6 26.5 mm; (2) posterior fundus myopic changes; (3) active subfoveal or juxtafoveal CNV on fluorescein angiography; (4) best-corrected visual acuity (BCVA) 6 20/400 at baseline, and (5) age over 18 years. The exclusion criteria were: (1) CNV due to other causes than pathological myopia; (2) retinal vasculopathies; (3) patients with subfoveal or juxtafoveal laser scar; (4) patients with previous treatment with other anti-angiogenic drugs (bevacizumab or pegaptanib) or with intravitreal triamcinolone or radiation; (6) ocular hypertension or glaucoma; (7) concomitant disease in the study eye, including uveitis, presence of pigment epithelial tears or rips, acute ocular or periocular infection, and central serous chorioretinopathy; (8) pregnancy or premenopausal women not using adequate contraception, and (9) patients with recent thromboembolic events.
Each patient underwent a complete ophthalmic examination including BCVA on a standard Early Treatment Diabetic Retinopathy Study (ETDRS) chart, slit-lamp examination, ocular tonometry, fundus examination and an optical coherence tomography (OCT; OCT Stratus v. 4.0 and Cirrus HD-OCT v. 2.0; Carl Zeiss Meditec, Inc., Dublin, Calif., USA) at baseline and then every 4-6 weeks during follow-up. Central foveal thickness (CFT) was measured automatically by OCT. We subtracted 60 m from the value obtained with the Cirrus HD-OCT for comparison with the values obtained with Stratus OCT. Fluorescein angiography was performed at baseline for all patients and when in doubt about CNV activity during follow-up. All patients had evidence of fluorescein angiography leakage at baseline that involved the fovea and was responsible for the decrease in visual acuity.
The need for retreatment was determined by a decrease in BCVA and/or metamorphopsia, the presence of intra-or subretinal fluid in the OCT and/or fluorescein angiography subfoveal or juxtafoveal leakage.
Main outcomes were BCVA change (ETDRS letter gain or loss) and CFT change measured by OCT during follow-up. The effects of previous PDT treatment and age on final visual acuity were considered secondary outcomes.
The presence of systemic or ocular side effects was evaluated at each visit during the follow-up time.
The study followed the tenets of the Declaration of Helsinki and was approved by the university clinic research committee. An informed consent document was reviewed and signed by all patients.
Statistical analysis was performed by means of a nonparametric Wilcoxon signed-rank test and two-tailed t test in order to compare continuous variables. Categorical variables were compared using the 2 test. The influence of age, sex, previous PDT and number of treatments on BCVA change was analyzed by means of multivariate linear regression. A p value ! 0.05 was considered statistically significant. All statistical tests were performed using SPSS version 16.0.1 software (SPSS Inc., Chicago, Ill., USA).
Results
Forty eyes of 39 patients (12 men and 27 women; median age, 55 years; range, 20-89 years) presenting with active myopic CNV were included in this study and treated with at least one injection of ranibizumab. Fifteen eyes had previously undergone unsuccessful PDT for myopic CNV with a mean of 2.9 sessions. Follow-up was at least 30 months for all eyes, and 26 eyes reached the 3 years of follow-up.
Mean BCVA was 55.4 ETDRS letters at baseline, 59.7 letters at 12 months (p = 0.07), 61.8 letters at 24 months (p = 0.008) and 63.4 letters at 36 months (p = 0.039). Twenty-five percent of the patients gained 6 15 letters (3 lines) at 12 months, 30% at 24 months and 35% at 36 months. An improvement of 6 0 letters occurred in 57.5% of the patients at 12 months, 70% at 24 months and 69% at 36 months. BCVA worsened by 6 15 letters in only 2 patients (5%) at 12 months, 3 patients (7.5%) at 24 months and 3 patients (11.5%) at 36 months ( fig. 1 ). There was no correlation between final BCVA and initial BCVA (p = 0.07). We analyzed the response to intravitreal ranibizumab at 6 months dividing the patients into three groups: responders (gain 6 5 letters); stable (gain between -4 and 4 letters) and nonresponders (loss 6 5 letters). At 6 months, 48.7% of the eyes were responders, 30.8% were stable and 20.5% were nonresponders. The type of response at 6 months was significantly associated with the type of response to intravitreal ranibizumab at A mean number of 7.6 (range, 2-19) treatments were performed during the follow-up time. A mean of 4.1 injections were performed in the first year, 2.4 in the second year and 1.1 in the third year. Twenty-five percent of the patients only had treatments during the first year of follow-up and 57% of the patients needed no treatment during the third year of follow-up. Final BCVA, previous PDT, sex and age were not significantly correlated with the number of ranibizumab injections (p = 0.77; p = 0.71; p = 0.28, and p = 0.55, respectively). Seventy-five percent of the patients needed 3 injections at the first 3 visits. There was no significant difference in initial BCVA (p = 0.20), final BCVA (p = 0.89), initial CFT (p = 0.95), final CFT (p = 0.10), age (p = 0.78), or total number of treatments (p = 0.11) between patients who had 3 initial injections and patients who did not. There was no association between previous PDT treatment and the need for 3 initial injections (p = 0.57).
A subgroup analysis was performed on eyes with and without previous PDT comparing these two groups regarding baseline characteristics (age, initial visual acuity, initial CFT) and response to intravitreal ranibizumab. No statistical difference (p 1 0.05) was found between patients previously treated with PDT and naïve patients regarding any of the mentioned baseline characteristics, mean BCVA and mean CFT during follow-up or the final number of treatments. The eyes previously treated with PDT ( fig. 3 ) No systemic or ocular side effects were registered during follow-up, including endophthalmitis, retinal detachments, ocular hypertension, intraocular inflammation and thromboembolic events. Types of response to intravitreal ranibizumab (number of eyes). There was a significant (p ! 0.001) association between the type of response at 6 months and the response at 12 months, 24 months and 36 months. 6M = 6 months; NR = nonresponders; S = stable; R = responders.
Discussion
The introduction of anti-VEGF therapies in ophthalmology revolutionized the way we treat the exudative form of age-related macular degeneration (AMD). Ranibizumab is an anti-VEGF drug approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of neovascular AMD, improving and stabilizing visual acuity of most of these patients [12, 13] . Pathophysiology of myopic CNV is different from CNV secondary to AMD. However, high levels of VEGF seem to be involved in the development of myopic CNV [14] . In theory, a similar response to AMD is expected in patients with myopic CNV treated with intravitreal ranibizumab.
Previous studies reporting clinical experience with ranibizumab in myopic CNV have shown promising results.
Silva et al. [10, 11] reported the short-term outcomes of myopic CNV treated with ranibizumab and then confirmed its efficacy at 12 months of follow-up. Mean visual acuity improved by 8 letters with a final BCVA of 59.6 letters at 1 year of follow-up. Twenty-four percent of the patients gained 6 15 letters at 12 months with a mean of 3.6 treatments [10, 11] . Monés et al. [15] reported in a study of 23 patients a mean gain of 9.53 letters at 12 months with 27% gaining more than 15 letters. Lalloum et al. [16] included 36 eyes in their study and BCVA improved from 0.2 at baseline to a final BCVA of 0.4 with 17 months of follow-up. Forty-six percent of the eyes gained more than 15 letters. In the present study, visual acuity significantly improved with a longer follow-up time. Mean BCVA improved from 55.4 letters at baseline to 59.7 letters at 12 months (p = 0.07), 61.8 letters at 24 months (p = 0.008) and 63.4 letters at 36 months (p = 0.039). Twenty-five percent of the patients gained 6 15 letters at 12 months, 30% at 24 months and 35% at 36 months. Eyes losing vision at 6 months had a worse visual prognosis. They had a much higher possibility of maintaining a negative score at the end of follow-up. Visual acuity change at 6 months can be a predictive factor of visual outcome (p ! 0.001).
We adopted a nonloading dose treatment protocol with a monthly follow-up and then an as-needed treatment regimen, as did the authors of the previously mentioned studies. This decision was based on the assumption that the greater improvement in visual acuity is achieved after the first injection of ranibizumab [10, 11, 17] and the fact that CNV is generally less extensive in myopic eyes than in eyes with AMD. These eyes have less intra-or subretinal fluid, which may contribute to a better response to intravitreal ranibizumab. A mean of 4.1 injections were performed in the first year, 2.4 in the second year and 1.1 in the third year. The number of treatments was not correlated with final visual acuity and no predictive factors for the need for retreatment were identified. Seventy-five percent of the eyes in our study needed 3 injections at the first 3 visits. However, there was no significant difference in final visual acuity between patients who needed 3 initial injections and patients who did not (p = 0.89). The final BCVA of the eyes who did not need 3 initial injections was 64 letters with a mean of 5. treatments at the end of the 36 months, so we believe that the adoption of a loading dose would be excessive, unnecessary and associated with higher risks. It is still uncertain which is the most effective treatment regimen for myopic CNV, and there are no studies comparing these two treatment modalities (loading dose vs. pro re nata) in the management of myopic CNV with ranibizumab.
There are some authors that adopted a loading dose of ranibizumab for myopic CNV. Lai et al. [18] , in a study with 16 eyes, noted a mean gain of 3 lines with a mean of 3.8 treatments at the end of 12 months. Eighty-one percent of the eyes only needed the loading dose. CalvoGonzalez et al. [19] included 67 eyes with myopic CNV treated with a loading dose of ranibizumab with a mean follow-up of 15.6 months. They noticed a mean gain of 12 letters at the end of the follow-up with a mean of 4.2 treatments. A total of 53.7% of the eyes received only 3 injections.
We noticed a significant decrease in CFT measured by OCT during the follow-up time, with a mean decrease of 80 m. In our series, a high proportion of patients had their baseline CFT measured with a Stratus OCT and their final CFT measured with a Cirrus HD-OCT. There is a difference in CFT measurement between these two OCTs, and this difference depends on the retinal disease in study [20] . CFT measures by Cirrus OCT are greater than by Stratus OCT. This difference can be explained by the individual segmentation algorithms of the different OCTs. Cirrus OCT identifies the thickness of the retina based on the distance between the inner limiting membrane and the outer band of the retinal pigment epithelium while Stratus OCT performs the outer alignment at the level of the photoreceptor inner/outer segment junction. To compare the two systems, we have made a conversion, subtracting 60 m from the value obtained with Cirrus HD-OCT [21, 22] , so we have to be careful with the interpretation of our CFT results as there could be some residual errors. Myopic CNV has less intra-and subretinal fluid, and the choroid is usually very thin in these patients, so OCT can sometimes be useless in the decision to treat these patients. That is one of the reasons why we included metamorphopsias as a retreatment criteria.
Visual acuity improvement was obtained in eyes with and without previous PDT treatment, with no significant difference in visual outcome between these two groups. The mechanisms of action of PDT and ranibizumab are different, so patients that had undergone unsuccessful PDT for myopic CNV still have an opportunity for visual acuity improvement when treated with ranibizumab for their recurrent CNV. Authors like Lalloum et al. [16] noticed a significantly higher improvement in visual acuity in naïve patients when compared with patients who had undergone previous PDT. They justified their results by the fact that PDT is often associated with fibrosis of the neovascular membrane and can facilitate the development and progression of chorioretinal atrophy.
A negative significant correlation was observed between age and final visual acuity (p = 0.03). Patients aged less than 55 years had a higher improvement in visual acuity when compared with patients aged 55 or more years. This relation was also demonstrated in previous studies with PDT for myopic CNV [23, 24] . Younger patients have smaller neovascular membranes and a healthier retinal pigment epithelium able to envelop the CNV. On the other hand, older patients have larger areas of chorioretinal atrophy [25] and other age-related retinal changes that could explain a worse visual prognosis.
No cases of endophthalmitis, stroke, or retinal detachment were registered during the follow-up. Particular care was taken to observe the peripheral retina before treatment, and prophylactic topical antibiotics were administered before and after the injection.
In conclusion, our results suggest that intravitreal ranibizumab appears to be safe and effective in the treatment of subfoveal and juxtafoveal myopic CNV. BCVA significantly improves by the end of the third year of follow-up with a high proportion of patients gaining or stabilizing visual acuity. Change in BCVA at 6 months can be a predictive factor of visual outcome. Younger patients seem to have a better prognosis, and no differences were identified in visual outcome between naïve patients and patients with previous PDT for myopic CNV. A randomized, multicentric clinical trial is necessary to definitely conclude on the safety and efficacy of intravitreal ranibizumab for CNV in pathological myopia.
